Volume 26, Number 7—July 2020
Research
Paradoxal Trends in Azole-Resistant Aspergillus fumigatus in a National Multicenter Surveillance Program, the Netherlands, 2013–2018
Table 2
Voriconazole classification (no. isolates) | No. (%) isolates |
||
---|---|---|---|
Itraconazole | Posaconazole | Isavuconazole | |
Voriconazole-susceptible (18) | |||
Susceptible | 0 | 1 (5.6) | 6/16 (37.5) |
Intermediate | 1 (5.6) | 2 (11.1) | NA |
Resistant |
17 (94.4) |
15 (83.3) |
10/16 (62.5) |
Voriconazole-intermediate (124) | |||
Susceptible | 0 | 4 (3.2) | 2/121 (1.7) |
Intermediate | 6 (4.8) | 19 (15.3) | NA |
Resistant |
118 (95.2) |
101 (81.5) |
119/121 (98.3) |
Voriconazole-resistant (498) | |||
Susceptible | 50 (10) | 8 (1.6) | 0/396 (0) |
Intermediate | 25 (5) | 28 (5.6) | NA |
Resistant | 423 (85) | 462 (92.8) | 396/396 (100) |
*Isavuconazole was not measured before 2014; therefore, denominator is different in comparison with itraconazole and posaconazole. NA, not applicable (no intermediate susceptibility category defined for isavuconazole).
Page created: May 05, 2020
Page updated: June 18, 2020
Page reviewed: June 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.